Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefit
Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether.
Merck has withdrawn it...